Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT3C1VN)

• DTT Name: Enzyme unspecific (Enz)
• Gene Name: NO-GeName
• DTT Type: Successful target; [1]
• Related Disease:
  Female genital tract inflammatory disorder [ICD-11: GA0Z]
  Human immunodeficiency virus disease [ICD-11: 1C60-1C62]
• UniProt ID: NOUNIPROTAC
• TTD ID: T10362

Molecular Interaction Atlas (MIA) of This DTT

2 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desoxyribonuclease	DMEZFXR	Female genital tract inflammation	GA0Z	Approved	[2], [3]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[1], [3]

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HTI-101	DMURXMJ	Obesity	5B81	Phase 2	[4]
VT-1129	DMCGK9H	Onchocerciasis	1F6A	Phase 2	[5]
ASC-101	DMVNCSK	Haematological malignancy	2B33.Y	Phase 1/2	[6]
BXCL702	DMY9L4C	Haematological malignancy	2B33.Y	Phase 1	[7]

7 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-11259	DMZ5NQP	Bacterial infection	1A00-1C4Z	Terminated	[8]
A-364	DMKL482	Bacterial infection	1A00-1C4Z	Terminated	[9]
APC-6336	DMBA4DK	Hepatitis C virus infection	1E51.1	Terminated	[10]
BM-13677	DMKITQN	Diabetic complication	5A2Y	Terminated	[11]
GW-278884	DMUG82P	Colorectal cancer	2B91.Z	Terminated	[12]
NZ-1002	DMINSRW	Lysosomal storage disease	5C56.Z	Terminated	[13]
SRI-3072	DMBEUN6	Mycobacterium infection	1B10-1B21	Terminated	[14]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-76341	DMT9N1I	Diabetic complication	5A2Y	Investigative	[15]

References

• [1] Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.
• [2] Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.
• [5] The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.
• [6] ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015550)
• [10] CN patent application no. 103263414, Application of 2,2'-(1,4-phenylene)di(benzimidazole-5-carboxylic acid) in preparation of antitumor drug.
• [11] Progress in medicinal chemistry, 1994. Page(448).
• [12] WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs.
• [13] Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993.
• [14] 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.
• [15] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.